Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

KymaThera pulls in $80m to bring breast cancer drug to clinic

Oct 7, 2026, 10:15 AM

Read Full Article → KymaThera pulls in $80m to bring breast cancer drug to clinic

KymaThera pulls in $80m to bring breast cancer drug to clinic

Translate article text

Choose a language and wait for the translated text.

KymaThera plans to dose the first patients in its Phase I trial on oral, selective PI3Kα inhibitor, K-1728, in breast cancer in Q4 2026.

KymaThera pulls in $80m to bring breast cancer drug to clinic | PharmaVoice